| Study | N | Chemotherapy | intrathecal | radiotherapy | CR (%) | PFS median mos | OS median mos |
| Pels et al. [38] | 65 | Methotrexate prednisone Ifosfamide vincristine cytarabine | Methotrexate | None | 61 | 21 | 50 |
| DeAngelis et al. [39] | 110 102 | MPV/cytarabine | Methotrexate | 36 - 45 Gy | 58
| 24 | 36,9 |
| Thiel et al. [26] | 551 | Arm 1: Methotrexate Arm 2: MTX + ifosfamide | - - | 45 Gy None | 35 12 | 18
| 32 37 |
| Hoang xuan et al. [40] | 50 | HD MTH, lomustine procarbazine | Methotrexate cytarabine | None | 42 | 12 | 14,3 |
| Gavrilovic et al. [41] | 57 | MPV | Methotrexate | 45 Gy in those aged < 60 year | 56 | 129 | 51 |
| Our series | 22 | HDMTX, VCR, procarbazine | Methotrexate cytarabine | 20 - 40 Gy | 58 | 25 | 29 |